The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment

被引：35

作者：

Lin, Mengmeng ^{[1
]}

Xiong, Weiping ^{[2
]}

Wang, Shiyuan ^{[1
]}

Li, Yingying ^{[1
]}

Hou, Chunying ^{[1
]}

Li, Chunyu ^{[1
]}

Li, Guohui ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China

[2] Shanghai Putuo Dist Liqun Hosp, Dept Cardiol, Shanghai, Peoples R China

来源：

FRONTIERS IN CARDIOVASCULAR MEDICINE | 2022年 / 8卷

关键词：

trastuzumab; cardiotoxicity; breast cancer; adverse reaction; rational drug use; ESC POSITION PAPER; ADJUVANT TRASTUZUMAB; HEART-FAILURE; MONOCLONAL-ANTIBODY; PLUS TRASTUZUMAB; OXIDATIVE STRESS; RANDOMIZED-TRIAL; FOLLOW-UP; CARDIAC DYSFUNCTION; CARDIOMYOCYTE DEATH;

D O I：

10.3389/fcvm.2021.821663

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In recent years, the incidence of breast cancer has been increasing on an annual basis. Human epidermal growth factor receptor-2 (HER-2) is overexpressed in 15-20% human breast cancers, which is associated with poor prognosis and a high recurrence rate. Trastuzumab is the first humanized monoclonal antibody against HER-2. The most significant adverse effect of trastuzumab is cardiotoxicity, which has become an important factor in limiting the safe use of the drug. Unfortunately, the mechanism causing this cardiotoxicity is still not completely understood, and the use of preventive interventions remains controversial. This article focuses on trastuzumab-induced cardiotoxicity, reviewing the clinical application, potential cardiotoxicity, mechanism and discussing the potential interventions through summarizing related researches over the past tens of years.

引用

页数：11

共 96 条

[1] Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial [J].

Advani, Pooja P. ;

Ballman, Karla V. ;

Dockter, Travis J. ;

Colon-Otero, Gerardo ;

Perez, Edith A. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) :581-+

[2] Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer [J].

Agus, DB ;

Gordon, MS ;

Taylor, C ;

Natale, RB ;

Karlan, B ;

Mendelson, DS ;

Press, MF ;

Allison, DE ;

Sliwkowski, MX ;

Lieberman, G ;

Kelsey, SM ;

Fyfe, G .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2534-2543

[3] Clinical and Prognostic Significance of sST2 in Heart Failure JACC Review Topic of the Week [J].

Aimo, Alberto ;

Januzzi, James L., Jr. ;

Bayes-Genis, Antoni ;

Vergaro, Giuseppe ;

Sciarrone, Paolo ;

Passino, Claudio ;

Emdin, Michele .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (17) :2193-2203

[4] An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity [J].

Anjos, Miguel ;

Fontes-Oliveira, Marta ;

Costa, Vera M. ;

Santos, Mario ;

Ferreira, Rita .

LIFE SCIENCES, 2021, 280

[5] Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+breast cancer patients: results from a single-center retrospective study [J].

Bergamini, Corinna ;

Torelli, Flavia ;

Ghiselli, Luca ;

Rossi, Andrea ;

Trevisani, Laura ;

Vinco, Giulia ;

Truong, Stella ;

Benfari, Giovanni ;

La Russa, Francesca ;

Golia, Giorgio ;

Molino, Annamaria ;

Vassanelli, Corrado .

MINERVA CARDIOANGIOLOGICA, 2017, 65 (03) :278-287

[6] HER-2, TOP2A and chromosome 17 alterations in breast cancer [J].

Beser, Ash Rehber ;

Tuzlali, Sitki ;

Guzey, Deniz ;

Guler, Semra Dolek ;

Hacihanefioglu, Seniha ;

Dalay, Nejat .

PATHOLOGY & ONCOLOGY RESEARCH, 2007, 13 (03) :180-185

[7] Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer A Randomized Clinical Trial [J].

Boekhout, Annelies H. ;

Gietema, Jourik A. ;

Kerklaan, Bojana Milojkovic ;

van werkhoven, Erik D. ;

Altena, Renske ;

Honkoop, Aafke ;

Los, Maartje ;

Smit, Willem M. ;

Nieboer, Peter ;

Smorenburg, Carolien H. ;

Mandigers, Caroline M. P. W. ;

van der Wouw, Agnes J. ;

Kessels, Lonneke ;

van der Velden, Annette W. G. ;

Ottevanger, Petronella B. ;

Smilde, Tineke ;

de Boer, Jaap ;

van Veldhuisen, Dirk J. ;

Kema, Ido P. ;

de Vries, Elisabeth G. E. ;

Schellens, Jan H. M. .

JAMA ONCOLOGY, 2016, 2 (08) :1030-1037

[8] Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies [J].

Bosch, Xavier ;

Rovira, Montserrat ;

Sitges, Marta ;

Domenech, Ariadna ;

Ortiz-Perez, Jose T. ;

de Caralt, Teresa M. ;

Morales-Ruiz, Manuel ;

Perea, Rosario J. ;

Monzo, Mariano ;

Esteve, Jordi .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (23) :2355-2362

[9] Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy [J].

Calvillo-Arguelles, Oscar ;

Abdel-Qadir, Husam ;

Michalowska, Maria ;

Billia, Filio ;

Suntheralingam, Sivisan ;

Amir, Eitan ;

Thavendiranathan, Paaladinesh .

CANADIAN JOURNAL OF CARDIOLOGY, 2019, 35 (02) :153-159

[10] 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial [J].

Cameron, David ;

Piccart-Gebhart, Martine J. ;

Gelber, Richard D. ;

Procter, Marion ;

Goldhirsch, Aron ;

de Azambuja, Evandro ;

Castro, Gilberto, Jr. ;

Untch, Michael ;

Smith, Ian ;

Gianni, Luca ;

Baselga, Jose ;

Al-Sakaff, Nedal ;

Lauer, Sabine ;

McFadden, Eleanor ;

Leyland-Jones, Brian ;

Bell, Richard ;

Dowsett, Mitch ;

Jackisch, Christian .

LANCET, 2017, 389 (10075) :1195-1205

← 1 2 3 4 5 6 7 8 9 10 →